Nadya Andini1, Anne Hu1, Luming Zhou2, Steven Cogill1, Tza-Huei Wang3, Carl T Wittwer2, Samuel Yang4. 1. Department of Emergency Medicine, Stanford University, Stanford, CA. 2. Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT. 3. Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD. 4. Department of Emergency Medicine, Stanford University, Stanford, CA; syang5@stanford.edu.
Abstract
BACKGROUND: The time required for bloodstream pathogen detection, identification (ID), and antimicrobial susceptibility testing (AST) does not satisfy the acute needs of disease management. Conventional methods take up to 3 days for ID and AST. Molecular diagnostics have reduced times for ID, but their promise to supplant culture is unmet because AST times remain slow. We developed a combined quantitative PCR (qPCR)-based ID+AST assay with sequential detection, ID, and AST of leading nosocomial bacterial pathogens. METHODS: ID+AST was performed on whole blood samples by (a) removing blood cells, (b) brief bacterial enrichment, (c) bacterial detection and ID, and (d) species-specific antimicrobial treatment. Broad-spectrum qPCR of the internal transcribed spacer between the 16S and 23S was amplified for detection. High-resolution melting identified the species with a curve classifier. AST was enabled by Ct differences between treated and untreated samples. RESULTS: A detection limit of 1 CFU/mL was achieved for Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus. All species were accurately identified by unique melting curves. Antimicrobial minimum inhibitory concentrations were identified with Ct differences of ≥1 cycle. Using an RNA target allowed reduction of AST incubation time from 60 min to 5 min. Rapid-cycle amplification reduced qPCR times by 83% to 30 min. CONCLUSIONS: Combined, sequential ID+AST protocols allow rapid and reliable detection, ID, and AST for the diagnosis of bloodstream infections, enabling conversion of empiric to targeted therapy by the second dose of antimicrobials.
BACKGROUND: The time required for bloodstream pathogen detection, identification (ID), and antimicrobial susceptibility testing (AST) does not satisfy the acute needs of disease management. Conventional methods take up to 3 days for ID and AST. Molecular diagnostics have reduced times for ID, but their promise to supplant culture is unmet because AST times remain slow. We developed a combined quantitative PCR (qPCR)-based ID+AST assay with sequential detection, ID, and AST of leading nosocomial bacterial pathogens. METHODS: ID+AST was performed on whole blood samples by (a) removing blood cells, (b) brief bacterial enrichment, (c) bacterial detection and ID, and (d) species-specific antimicrobial treatment. Broad-spectrum qPCR of the internal transcribed spacer between the 16S and 23S was amplified for detection. High-resolution melting identified the species with a curve classifier. AST was enabled by Ct differences between treated and untreated samples. RESULTS: A detection limit of 1 CFU/mL was achieved for Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus. All species were accurately identified by unique melting curves. Antimicrobial minimum inhibitory concentrations were identified with Ct differences of ≥1 cycle. Using an RNA target allowed reduction of AST incubation time from 60 min to 5 min. Rapid-cycle amplification reduced qPCR times by 83% to 30 min. CONCLUSIONS: Combined, sequential ID+AST protocols allow rapid and reliable detection, ID, and AST for the diagnosis of bloodstream infections, enabling conversion of empiric to targeted therapy by the second dose of antimicrobials.
Authors: Nathan G Schoepp; Eugenia M Khorosheva; Travis S Schlappi; Matthew S Curtis; Romney M Humphries; Janet A Hindler; Rustem F Ismagilov Journal: Angew Chem Int Ed Engl Date: 2016-06-30 Impact factor: 15.336
Authors: Qing Li; Jean Y Lee; Rosario Castillo; Mark S Hixon; Catherine Pujol; Venkata Ramana Doppalapudi; H Michael Shepard; Geoffrey M Wahl; Thomas J Lobl; Ming Fai Chan Journal: Antimicrob Agents Chemother Date: 2002-05 Impact factor: 5.191
Authors: Justin Hardick; Helen Won; Kevin Jeng; Yu-Hsiang Hsieh; Charlotte A Gaydos; Richard E Rothman; Samuel Yang Journal: J Clin Microbiol Date: 2012-05-09 Impact factor: 5.948
Authors: Stephanie I Fraley; Justin Hardick; Billie J Masek; Billie Jo Masek; Pornpat Athamanolap; Richard E Rothman; Charlotte A Gaydos; Karen C Carroll; Teresa Wakefield; Tza-Huei Wang; Samuel Yang Journal: Nucleic Acids Res Date: 2013-08-09 Impact factor: 16.971
Authors: Xi Yang; Marjan M Hashemi; Nadya Andini; Michelle M Li; Shuzhen Kuang; Karen C Carroll; Tza-Huei Wang; Samuel Yang Journal: J Antimicrob Chemother Date: 2020-07-01 Impact factor: 5.790
Authors: Marjan M Hashemi; Nikhil Ram-Mohan; Xi Yang; Nadya Andini; Nicholas R Gessner; Karen C Carroll; Tza-Huei Wang; Samuel Yang Journal: J Clin Microbiol Date: 2020-11-18 Impact factor: 5.948
Authors: Kristel C Tjandra; Nikhil Ram-Mohan; Ryuichiro Abe; Marjan M Hashemi; Jyong-Huei Lee; Siew Mei Chin; Manuel A Roshardt; Joseph C Liao; Pak Kin Wong; Samuel Yang Journal: Antibiotics (Basel) Date: 2022-04-12
Authors: Britney Forsyth; Peter Torab; Jyong-Huei Lee; Tyler Malcom; Tza-Huei Wang; Joseph C Liao; Samuel Yang; Erik Kvam; Chris Puleo; Pak Kin Wong Journal: Biosensors (Basel) Date: 2021-08-22